News & Analysis on Clinical Trial Services & Contract Research And Development
Aetion: Johnson & Johnson investment
By Jenni Spinner
- Last updated on
Healthcare technology company Aetion has landed a $19m extension to Series B funding, with investment from three new shareholders: Johnson & Johnson Innovation, EDBI, and Greenspring Associates. The infusion brings the company’s total Series B funding to $82m.
Scott Gottlieb, Aetion’s board director and former US Food and Drug Administration (FDA) commissioner, said, “The new investment will help Aetion define and advance real-world evidence standards in the US and across the globe.”
The funding reportedly will be used to expand the company’s Evidence Platform capabilities, aligning stakeholders with the goal of assessing the safety, effectiveness, and value of medications, and to advance its global effort in establishing standards for real-world evidence (RWE).